Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of their body weight while reducing osteoarthritis pain.

Eli LillyLLY is putting the "obesity field on notice again," an analyst said Thursday after the company's experimental ...